Added to YB: 2025-12-16
Pitch date: 2025-12-12
GSK [bullish]
GSK plc
+0.8%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 73.3B
Pitch Price
GBP 18.19
Price Target
N/A
Dividend
3.34%
EV/EBITDA
8.97
P/E
13.73
EV/Sales
2.71
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 12/12/2025 - GSK – Pipeline progress
GSK (update): Strong pipeline momentum w/ Blujepa approved for uGC (600k+ US cases annually), Arexvy RSV vaccine CHMP positive opinion for adults 18+ (158k EU hospitalizations), depemokimab positive for severe asthma (3m Europeans) & COPD (40m+ Europeans). 62 pipeline assets undervalued at 10.2x 2026 EPS, 3.8% yield.
Read full article (1 min)